Replimune (REPL) Consolidated Net Income (2017 - 2026)
Replimune (REPL) posted Consolidated Net Income of -$73.2 million for Q1 2026, down 3.14% sequentially from -$70.9 million in Q4 2025, and up 1.34% YoY from -$72.2 million in Q1 2025.
Analysis
Replimune (REPL) Consolidated Net Income (2017 - 2026) Analysis & Trends
Replimune has reported Consolidated Net Income for 10 years, with the latest figure at -$73.2 million in Q1 2026.
- Quarterly Consolidated Net Income rose 1.34% year-over-year to -$73.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$395.8 million (down 60.01% YoY) and the FY2026 annual result came in at -$313.9 million, down 26.91% from the prior year.
- Consolidated Net Income slipped to -$73.2 million in Q1 2026 per REPL's latest filing, from -$70.9 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at -$31.6 million in Q1 2022 and troughed at -$128.7 million in Q2 2025.
- A 5-year average of -$62.6 million and a median of -$53.8 million in 2024 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2022 and 2025: Consolidated Net Income surged 51.52% in 2022, then plunged 139.39% in 2025.
- Over 5 years, Consolidated Net Income stood at -$39.7 million in 2022, then fell by 28.8% to -$51.1 million in 2023, then declined by 29.77% to -$66.3 million in 2024, then declined by 6.94% to -$70.9 million in 2025, then retreated by 3.14% to -$73.2 million in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$73.2 million, -$70.9 million, and -$122.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - | -68.87 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -68.87 Mn |
| Mar 31, 2026 | -73.17 Mn |
| Dec 31, 2025 | -70.93 Mn |
| Sep 30, 2025 | -82.08 Mn |
| Jun 30, 2025 | -87.18 Mn |
| Mar 31, 2025 | -74.14 Mn |
| Dec 31, 2024 | -66.37 Mn |
| Sep 30, 2024 | -53.06 Mn |
| Jun 30, 2024 | -53.77 Mn |
| Mar 31, 2024 | -55.05 Mn |
| Dec 31, 2023 | -51.15 Mn |
| Sep 30, 2023 | -60.04 Mn |
| Jun 30, 2023 | -49.56 Mn |
| Mar 31, 2023 | -49.25 Mn |
| Dec 31, 2022 | -39.69 Mn |
| Sep 30, 2022 | -43.10 Mn |
| Jun 30, 2022 | -42.25 Mn |
| Mar 31, 2022 | -31.86 Mn |
| Dec 31, 2021 | -29.61 Mn |
| Sep 30, 2021 | -29.17 Mn |